secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001104659-25-042570
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty
--------------------------------------------------------------------------------

- License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.
- Avenue to receive $2M total within 90 days: $1M due in 30 days, $1M due in 90 days.
- Potential future payments: up to $5M development milestones, up to $17M commercial milestones, 1.75% royalty on net sales.
- Avenue repurchases 14,777 shares from AnnJi for $1.00 aggregate and pays $0.2M for AnnJi legal expenses.
- 48-month non-compete for competing products in US, Canada, EU, UK, and Israel after termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465925042570/0001104659-25-042570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465925042570/tm2513615d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-042570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer